Navigation Links
Why Cancer Symptoms May Elude M.D.
Date:2/24/2012

nowledge," lead author Georgios Lyratzopoulos, of Cambridge University, said in a journal news release. "Medical research in recent decades has prioritized improving cancer treatments, but knowledge about the 'symptom signature' of common cancers and practical solutions on how best to diagnose them is still emerging."

Martin Guilliford, of King's College London, wrote in an accompanying editorial that the findings raise several questions that should be tested in future research.

He said some of those questions are: "Do modes of cancer presentation vary systematically between different groups of patients? Are (family doctors) more reluctant to refer young or non-white patients for investigation of possible cancer? Are participants in these groups less willing to accept a referral to investigate possible cancer?"

More information

The American Academy of Family Physicians has more about cancer diagnosis and tests.

-- Robert Preidt

SOURCE: The Lancet Oncology, news release, Feb. 21, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Study Supports CT-Based Virtual Colonoscopy to Spot Colon Cancer
2. Breaking down cancers defense for future vaccines
3. Scripps Florida scientists uncover inflammatory circuit that triggers breast cancer
4. Colonoscopy prevents deaths from colon cancer
5. Obesity may modify the association between alcohol consumption and the risk of colorectal cancer
6. Colon Cancer Alliance and American College of Radiology demand Medicare cover virtual colonoscopy
7. Stronger intestinal barrier may prevent cancer in the rest of the body, new study suggests
8. FDA Moves to Head Off Shortages of 2 Cancer Drugs
9. Mapping of protein inhibitors facilitates development of tailor-made anticancer agents
10. New blood test for early cancer detection developed by Ben-Gurion University researchers
11. Telomere failure, telomerase activation drive prostate cancer progression
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Why Cancer Symptoms May Elude M.D.
(Date:10/18/2014)... Stafford Communications , a New ... breast cancer awareness program called “Sleep Pink” on October ... pajama parties where women and men can promote awareness ... of the program, Stafford’s employees wore pink pajamas and ... Page. In exchange, Stafford Communications and the makers of ...
(Date:10/18/2014)... humans have a natural opioid system in the brain. ... Berlin, has found that the opioid system of pathological ... The work was carried out by a group of ... by the Medical Research Council. This work is being ... Berlin., Gambling is a widespread behaviour with about 70% ...
(Date:10/18/2014)... 18, 2014 Mirena lawsuits ( http://www.injurybeacon.com/mirena-iud/lawsuit/ ... sustain serious injuries when it spontaneously migrated from its ... U.S. courts, Bernstein Liebhard LLP reports. According to an ... on Multidistrict Litigation (JPML) on October 15th, at least ... litigation underway in the U.S. District Court, Southern District ...
(Date:10/18/2014)... 18, 2014 The sudden closure of ... community has left hundreds of patients scrambling for ... their care with the two closed offices of another ... have been referred to the center and now are ... and procedures. This mysterious event has left literally thousands ...
(Date:10/18/2014)... Sharon Ganzhorn, a radiologic technologist at ... she created an Amazon Wish List for a local ... only be met, but that the community would also ... in just a week’s time. , Thanks to ... and country, Ganzhorn and a team of volunteers, including ...
Breaking Medicine News(10 mins):Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 2Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 3Health News:Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 4Health News:New Invisalign Leader Comes to Washington Heights and the Bronx 2Health News:New Invisalign Leader Comes to Washington Heights and the Bronx 3Health News:ED Nurse at Riverside Tappahannock Hospital Orchestrates Donation of $2,500 in Pet Supplies to Local Animal Shelter 2Health News:ED Nurse at Riverside Tappahannock Hospital Orchestrates Donation of $2,500 in Pet Supplies to Local Animal Shelter 3Health News:ED Nurse at Riverside Tappahannock Hospital Orchestrates Donation of $2,500 in Pet Supplies to Local Animal Shelter 4
... Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced today ... present an overview of the,company at two investor conferences ... will present at the CIBC World Markets 18th Annual,Healthcare ... ET (5:35,a.m. PT). In addition, Ostrach will present at ...
... Inc. today,announced the initiation of a phase 1 ... treatment of hypertension. AR9281 is a "first-in-class,",orally-active inhibitor ... the treatment of hypertension. The trial will enroll ... the safety, tolerability,pharmacokinetics and pharmacodynamics for single ascending ...
... Nov. 1 Amira Pharmaceuticals, Inc. announced,completion of ... Amira,s,internally discovered oral drug candidate for the treatment ... also announced the start,of a Phase 1 trial ... targets the,same inflammatory response. AM103 and AM803 ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... 1, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global ... Q3 2007 Financial Highlights - Product sales up 41% ... $608.7 million; - Net cash provided by operating activities ... growth now expected to be at least 30% (Q2 guidance: ...
... - An Innovative Approach to Preventing Kidney Damage during ... ... Systems Inc. (Amex: PLC ), a,company focused on innovative cardiac ... RenalGuard,System(TM) during Renal Week, the American Society of Nephrology,s 40th,Annual Meeting ...
Cached Medicine News:Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30
(Date:10/17/2014)... 17, 2014   DaVita HealthCare Partners Inc. ... the nation,s largest and most innovative health care ... – the company,s award-winning, leadership development and cultural ... teammates from around the globe were in attendance ... Academy is a two-day one-of-a-kind experience for new ...
(Date:10/16/2014)... 16, 2014  Cepheid (Nasdaq: CPHD ) ... of $115.2 million, representing growth of 15% from $100.1 ... in the third quarter of 2014 was $(7.2) million, ... of $(1.4) million, or $(0.02) per share, in the ... compensation expense, amortization of debt discount and transaction costs, ...
(Date:10/16/2014)... Eight finalists, all representing outstanding innovation in pediatric medical ... a chance to compete for one of two $50,000 ... Annual Pediatric Surgical Innovation Symposium hosted by ... 2014. Selected from a competitive field of ... the finalists are: , Creative Vascular ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4
... TAMPA, Fla., April 16, 2007 /PRNewswire/ -- ... that it has received orphan drug designation ... its anti-viral therapy,ganciclovir, for the treatment of ... by Laboratoires Thea in Europe under,the brand ...
... - Data Presented at 2007 APA Meeting ... -- Data,from four new studies examining safety ... (SNRI) being studied as a potential treatment ... presented today at the,2007 American Psychiatric Association ...
Cached Medicine Technology:Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: